Dados B3 › CRTE3 × EMBJ3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | CRTE3 | EMBJ3 | year |
|---|---|---|---|
| ROE | -19.5%! | 10.3% | 2025 |
| ROIC | -509.2%! | 11.5% | 2024 |
| ROA | -13.4% | 2.8% | 2025 |
| Gross margin | 38.8% | 20.1% | 2022 |
| EBIT margin | 32.3% | -2.4% | 2022 |
| Net margin | 16.6% | -4.5% | 2022 |
| Net debt/EBITDA | -0.97x | 8.78x | 2022 |
| Current ratio | 4.11x | 1.50x | 2025 |
| Revenue growth (1y) | -100.0%! | 11.4% | 2023 |
| Revenue growth (5y CAGR) | -4.5% | 4.5% | 2022 |
| Piotroski F-Score | 3/9! | 8/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | CRTE3 | EMBJ3 | year |
|---|---|---|---|
| P/E | — | 29.66x | None × 2025 |
| P/B | — | 3.06x | None × 2025 |
| EV/EBITDA | — | 12.06x | None × 2025 |
| FCF yield | — | 3.1% | None × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:14 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it